Non-invasive approaches for lung cancer diagnosis
- 222 Downloads
Lung cancer is the leading cause of cancer-related deaths worldwide. The case-fatality rate of lung cancer remains exceptionally high at 95% despite numerous medical advancements in therapeutic strategies in the last decades. However, patients diagnosed at Stage I are commonly curable and have a 5-year survival rate of 50–80%. Unfortunately, delayed diagnosis of lung cancer has been unavoidable and is an important factor in the overall outcome of treatment. Accordingly, screening of high-risk individuals is likely to have hugely beneficial outcomes for patient survival. Current screening approaches include low-dose computed tomography and chest X-ray. Recently, alternative approaches for lung cancer screening have been developed including analysis of biomarkers, including DNA, RNA, proteins, and antibodies in blood, sputum, bronchoalveolar lavage (BAL), and breath. Biomarker analysis would also provide critical information regarding tumor growth pattern, cells of origin of tumor, subtype of lung cancer, and/or drug metabolism as well as monitor patient prognosis. Novel non-invasive lung cancer diagnostic strategies could improve and complement the success of CT-scan and chest X-ray.
KeywordsLung cancer Diagnosis Non-invasive
Guillermo Barreto is funded by the “LOEWE-Initiative der Landesförderung” (Wiesbaden Germany) (III L 4–518/15.004 2009) and the “Deutsche Forschungsgemeinschaft” (DFG, Bonn, Germany) (BA 4036/1-2). This work was done according to the program of competitive growth of the Kazan Federal University and the Russian Government.
Compliance with ethical standards
This article does not contain any studies with human participants or animals performed by any of the authors.
Conflict of interest
The authors declare that they have no conflict of interest.
- 6.Program NCR. Annual Reports accessed from https://www.ncrpindia.org/ on 05.06.2017.
- 9.Pass HI CD JD, Minna JD, Scagliotti GV, Turrisi AT Principles and Practice of Lung Cancer . The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC) Lippincott Williams and Wilkins, a Wolters Kluwer business: Alphen aan den Rijn, The Netherlands . 2010.Google Scholar
- 12.Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung cancer. 2005;50:355–74.CrossRefPubMedGoogle Scholar
- 15.Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev. 2007;3:CD006157.Google Scholar
- 38.Oshita F, Nomura I, Yamada F, Kato F, Tanaka F, Noda F. Detection of K-ras mutations of bronchoalveolar lavage fluid cells aids the diagnosis of lung cancer in small pulmonary lesions. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999;5:617–20.Google Scholar